CRO

VeriFast Names Rob Strickland, CRO, Chris Pornaras, Chief Commercial Officer

Retrieved on: 
Wednesday, October 5, 2022

VeriFast , the AI-powered Verification-as-a-Service platform that automates financial analysis and decision making for tenant screening, mortgage underwriting and business lending , today announced the appointment of New York-based FinTech veteran Rob Strickland, CRO and Canadian banking veteran Chris Pornaras, Chief Commercial Officer to its leadership team.

Key Points: 
  • VeriFast , the AI-powered Verification-as-a-Service platform that automates financial analysis and decision making for tenant screening, mortgage underwriting and business lending , today announced the appointment of New York-based FinTech veteran Rob Strickland, CRO and Canadian banking veteran Chris Pornaras, Chief Commercial Officer to its leadership team.
  • VeriFast Co-Founder and COO Chad Guziewicz said, VeriFasts solution adoption within the U.S. and Canadian mortgage markets has greatly increased over the past year.
  • Strickland joins VeriFast from Brimma, a mortgage tech provider specializing in delivering modern technology integration and innovation.
  • VeriFast provides a single-source configurable API platform that allows companies to immediately validate customers ability to pay while eliminating fraud.

Alimentiv, Satisfai Health, and Virgo Announce Partnership to use AI-driven technology to Enhance Clinical Trials in IBD and other GI Diseases

Retrieved on: 
Wednesday, October 5, 2022

"This synergy of Satisfai and Virgo with Alimentiv is a positive development for patients with IBD and the drug development space.

Key Points: 
  • "This synergy of Satisfai and Virgo with Alimentiv is a positive development for patients with IBD and the drug development space.
  • Clinical trials have many pain points, and this strategic partnership will enable advances in improving the efficiency of clinical trials and make some significant changes to how trials arerun", said Jeff Smith, CEO of Alimentiv.
  • "We are delighted to enter this arrangement to bring the next generation of imaging technology to clinical trials in gastroenterology."
  • "Working with Virgo, we are excited to bring AI-driven solutions to the IBD clinical trials arena.

Alimentiv, Satisfai Health, and Virgo Announce Partnership to use AI-driven technology to Enhance Clinical Trials in IBD and other GI Diseases

Retrieved on: 
Wednesday, October 5, 2022

LONDON, ON, Oct. 5, 2022 /PRNewswire/ -- Alimentiv Inc. ("Alimentiv"), Satisfai Health, Inc ("Satisfai"), and Virgo Surgical Video Solutions, Inc. ("Virgo") today announced a strategic partnership to revolutionize central reading, data capture, decision support, and patient recruitment in the clinical trial domain for Inflammatory Bowel Disease (IBD) and allied GI conditions. Satisfai, a global leader in developing artificial intelligence solutions for gastroenterology, and Virgo, an industry leader in endoscopy video capture technology, will leverage their combined strengths to work in partnership with Alimentiv, a leading CRO in gastroenterology, to realize the full potential of AI-powered precision imaging in the GI clinical trials space.

Key Points: 
  • "This synergy of Satisfai and Virgo with Alimentiv is a positive development for patients with IBD and the drug development space.
  • Clinical trials have many pain points, and this strategic partnership will enable advances in improving the efficiency of clinical trials and make some significant changes to how trials arerun", said Jeff Smith, CEO of Alimentiv.
  • "We are delighted to enter this arrangement to bring the next generation of imaging technology to clinical trials in gastroenterology."
  • "Working with Virgo, we are excited to bring AI-driven solutions to the IBD clinical trials arena.

Avolon Announces Leadership Appointments

Retrieved on: 
Wednesday, October 5, 2022

Avolon, the international aircraft leasing company, announces appointments to the roles of Chief Financial Officer (CFO), Chief Operating Officer (COO), and Chief Risk Officer (CRO).

Key Points: 
  • Avolon, the international aircraft leasing company, announces appointments to the roles of Chief Financial Officer (CFO), Chief Operating Officer (COO), and Chief Risk Officer (CRO).
  • Andy Cronin, Avolon CEO, commented: Todays appointments further strengthen our leadership team and position us as an industry leader.
  • Jim joined Avolon in 2017 as a member of the OEM Team and was most recently Avolons Head of Portfolio Management.
  • Avolon is a global leader in aircraft leasing with an owned, managed and committed fleet, as of 30 June 2022 of 851 aircraft.

Mindset Pharma Selects Lead Clinical Candidates From “Family 2” of its Next Generation Psychedelic Drug Portfolio

Retrieved on: 
Wednesday, October 5, 2022

Through a world class scientific collaboration among the Mindset, MSRD and Otsuka Pharmaceuticals teams, Mindset has successfully moved its Family 2 program forward.

Key Points: 
  • Through a world class scientific collaboration among the Mindset, MSRD and Otsuka Pharmaceuticals teams, Mindset has successfully moved its Family 2 program forward.
  • After extensively screening multiple drug candidates in preclinical studies, we were able to identify not one, but two novel drug candidates to potentially advance to clinical human trials.
  • We are delighted to have reached this major milestone in our programs development, said James Lanthier, CEO of Mindset Pharma.
  • Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.

Global Bioanalytical Testing Services Markets, 2021-2022 & 2027: Leading Growth Opportunity Areas in Customized Bioassay and Biomarker Testing Services - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 5, 2022

This report on global bioanalytical testing services identifies some of the leading growth opportunity areas in terms of customized bioassay and biomarker testing services, highlighting the growing trend of CRO subcontracting to specifically cater to the specialized drug development and accuracy needs.

Key Points: 
  • This report on global bioanalytical testing services identifies some of the leading growth opportunity areas in terms of customized bioassay and biomarker testing services, highlighting the growing trend of CRO subcontracting to specifically cater to the specialized drug development and accuracy needs.
  • Bioanalytical testing is one of the core aspects of drug development.
  • The testing modules include biomarker testing, immunogenicity testing, toxicology, pharmacokinetics (PK), and pharmacodynamics (PD).
  • What are key trends driving and restricting the outsourcing of bioanalytical testing services?

Global Oncology Based In-Vivo CRO Market Report 2022: Rising Outsourcing from Pharma Companies Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 5, 2022

The "Oncology Based In-Vivo CRO Market Analysis, By Model, By Indication, and by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Oncology Based In-Vivo CRO Market Analysis, By Model, By Indication, and by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The oncology based in-vivo CRO market size is estimated to be USD 998.96 million in 2021 and is expected to witness a CAGR of 8.75% during the forecast period 2022-2029.
  • The rising frequency with which big pharmaceutical companies outsource their R&D operations and increasing CROs' demand are projected to drive the market growth in near future.
  • Segmentation: Oncology Based In-Vivo CRO Market Report 2021-2029 Model (Revenue, USD Million)

Iterable Strengthens Executive Team with New Chief Revenue Officer, Chief People Officer, and Chief Information Security Officer

Retrieved on: 
Tuesday, October 4, 2022

Bobby Jaffari joins the company as Chief Revenue Officer (CRO), Sejal Patel Daswani joins as Chief People Officer (CPO), and Vasu Kohli is promoted to the role of Chief Information Security Officer (CISO) from within Iterable.

Key Points: 
  • Bobby Jaffari joins the company as Chief Revenue Officer (CRO), Sejal Patel Daswani joins as Chief People Officer (CPO), and Vasu Kohli is promoted to the role of Chief Information Security Officer (CISO) from within Iterable.
  • Iterable recently surpassed 1,000 customers worldwide and expanded its global presence in Australia and New Zealand.
  • Together with Iterables current leadership team , these new executives will ensure Iterables business, culture, and customers continue to thrive as the company scales.
  • Before Iterable, Vasu led risk management and compliance as Sr. Director, Information Security, and GRC Leader, at Palo Alto Networks (NASDAQ: PANW).

NAMSA Acquires UK-Based Perfectus Biomed Group to Enhance Customized Microbiological Solutions

Retrieved on: 
Tuesday, October 4, 2022

NAMSA , a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, announced today its acquisition of Perfectus Biomed Group , a UK-based laboratory providing customized microbiological services.

Key Points: 
  • NAMSA , a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, announced today its acquisition of Perfectus Biomed Group , a UK-based laboratory providing customized microbiological services.
  • NAMSA very much looks forward to expanding its European suite of laboratory services with the addition of Perfectus Biomed Group, commented Dr. Christophe Berthoux , NAMSA CEO.
  • Perfectus brings an unmatched level of expertise and depth of knowledge in customized microbiological testing solutions.
  • Perfectus Biomed Group is delighted to join NAMSA in its mission to deliver best-in-class global MedTech solutions through its people, expertise and technology.

BEKHealth Launches Suite of Solutions to Allow Pharmaceutical Sponsors to Design Better Studies, More Precisely Identify Sites, and Recruit Patients Faster

Retrieved on: 
Tuesday, October 4, 2022

STAMFORD, Conn., Oct. 4, 2022 /PRNewswire-PRWeb/ -- BEKHealth, a clinical research operating platform, today announced the launch of several new solutions to help pharmaceutical companies and clinical research organizations streamline protocol design processes, find eligible and engaged patients with greater speed and efficiency, and match protocols with sites capable of executing trials. The new products include:

Key Points: 
  • Taking all inclusion and exclusion criteria into consideration, BEKInsights produces a high-level report of patient counts and insights that can be used to inform necessary changes to protocol design.
  • BEKHealth utilizes BEKMatch to find the right fit sites for upcoming and current clinical trials.
  • BEKLink is a patient outreach program that enables pharma and clinical researchers to conduct patient outreach and gauge interest among eligible candidates.
  • BEKHealth Corp. enables healthcare organizations of all sizes to quickly enter or expand clinical research.